Although clinical trials of AURA series illustrated that non-small cell lung cancer (NSCLC) with <i>EGFR</i> T790M mutation can benefit from osimertinib, only five LSCC patients were enrolled in total; moreover, the efficacy for LSCC was not shown in the results.
However, Aurora-A overexpression combined with exposure to TPA and the mutagen 7,12-dimethylbenz(a)anthracene accelerated SCC development with greater metastatic activity than control mice, indicating that Aurora-A cannot initiate skin carcinogenesis but rather promotes the malignant conversion of skin papillomas.
The expression patterns of STK15 were examined by immunohistochemistry in 80 lung squamous cell carcinomas and adenocarcinomas and 20 normal lung tissues.